CardioExchange Archive

February 2nd, 2012

Study Explores Role of Periprocedural Dabigatran in AF Ablation

Larry Husten, PHD

As dabigatran becomes more widely used in AF patients, electrophysiologists are trying to figure out how to handle anticoagulation in patients taking the drug and for whom AF ablation is planned. In a new study published in the Journal of the American College of Cardiology, Dhanunjaya Lakkireddy and colleagues report on a multicenter, observational study of 290 patients […]

---

February 1st, 2012

Meta-Analysis Confirms Benefits of Statins in Women

Larry Husten, PHD

Although clinical trials have consistently found a beneficial effects for statins, some critics have questioned the strength of the evidence in women, who are often under-represented in clinical trials.  A large new meta-analysis published in the Journal of the American College of Cardiology provides the best evidence yet that the relative reductions in events observed in men […]

---

January 31st, 2012

Consensus Document Provides Roadmap to Uptake of TAVR in U.S.

Larry Husten, PHD

Following the recent FDA approval of transcatheter aortic valve replacement (TAVR), the ACC, AATS, SCAI, and STS — in conjunction with several other medical organizations — have released a critical consensus document to guide use of the new landmark procedure. “We have tried to collate the evidence into a coherent road map for judicious use, rational dispersion, […]

---

January 31st, 2012

Robert Harrington Leaving Duke for Stanford University

Larry Husten, PHD

Robert Harrington will be leaving his position as the director of the Duke Clinical Research Institute, a position he has held since 2006, to become the new chair of the department of medicine at Stanford University. Harrington was also the Richard S. Stack MD Distinguished Professor at Duke University School of Medicine. The news was publicly announced […]

---

January 31st, 2012

Appropriate Use Criteria for Revascularization Updated

Larry Husten, PHD

The ACC, AHA, and other organizations have released updated appropriate use criteria for coronary revascularization. The 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update incorporates data from the SYNTAX trial on the indications for PCI and CABG in patients with symptomatic, multivessel disease, as well as data from the CathPCI registry. Here are some of the key ratings: […]

---

January 30th, 2012

Very Large Observational Study Finds Significant Mortality Advantage for CABG Over PCI in High-Risk Patients

Larry Husten, PHD

Although PCI has a small, early mortality benefit compared to CABG in high-risk patients, after the first year a striking survival advantage for CABG develops, according to results of the ASCERT study, presented on Monday at the annual meeting of the Society of Thoracic Surgeons (STS). Fred Edwards presented the high-risk subset of ASCERT (ACCF-STS Database Collaboration […]

---

January 26th, 2012

NHLBI Launches Two Large Cardiac Arrest Treatment Trials

Larry Husten, PHD

The NHLBI today announced the launch of two large clinical trials evaluating treatments for out-of-hospital cardiac arrest. The Continuous Chest Compressions (CCC) trial will randomize 23,600 people with out-of-hospital cardiac arrest to either standard CPR or continuous chest compressions, both delivered by paramedics or fire fighters. In recent years, studies published in the New England Journal of Medicine,  JAMA, and the Lancet have provided evidence […]

---

January 26th, 2012

Big Drop in MI Incidence and Fatality in England

Larry Husten, PHD

Since 2002, the incidence of acute MI in England has dropped by one-half and the case fatality rate by one-third, according to a new study published in BMJ. The overall decline in deaths from MI is about equally due to improvements in the prevention of MI and the treatment of MI. Kate Smolina and colleagues analyzed data from […]

---

January 25th, 2012

Huge Study Finds Risk Factors Do In Fact Predict Risk

Larry Husten, PHD

An enormous new meta-analysis confirms the important role that risk factors play over a lifetime in the development of cardiovascular disease. In a paper published in the New England Journal of Medicine, Jarett Berry and colleagues report on the meta-analysis from the Cardiovascular Lifetime Risk Pooling Project, which contains data from 18 epidemiological studies including more than one-quarter million […]

---

January 25th, 2012

FDA Rejects Proposed Chronic Kidney Disease Indication for Vytorin

Larry Husten, PHD

The FDA rejected a new indication for Merck’s Vytorin and Zetia (ezetimibe plus simvastatin and ezetimibe alone) in chronic kidney disease patients. As a consolation prize, however, the agency approved a new label for Vytorin that will incorporate the results of SHARP (Study of Heart and Renal Protection), which found that the drug combination reduced the incidence […]

---